Submitted by medscape9178 in health
By the first quarter 2022, 57% of US adults with type 2 diabetes taking an incretin-based agent were taking a GLP-1 receptor agonist; DPP-4 inhibitor use fell to 39% of these scripts.
Submitted by medscape9178 in health
By the first quarter 2022, 57% of US adults with type 2 diabetes taking an incretin-based agent were taking a GLP-1 receptor agonist; DPP-4 inhibitor use fell to 39% of these scripts.